Search Results

AngioSoma, Inc. has hired David Croom as an Executive Vice President. Mr. Croom brings decades of experience in finance, sales, and operations to the AngioSoma team.

Greenwald’s experience in public relations and marketing will play a key role in the growth of AngioSoma

AngioSoma, Inc. (OTC PINK:SOAN) has added Robert Chicoski as its Chief Financial Officer and Treasurer. Chicoski has decades of corporate financial, tax, audit and forensic accounting experience to the AngioSoma team. Headquartered in Richland, Washington, AngioSoma, Inc. is a fast-growing company focused on providing medical research, development and treatment

AngioSoma, Inc. has added Steven F. Penderghast to its Board of Directors. Penderghast has experience working in medical sciences, as well as his leadership roles at major health care organizations, including Baxter Healthcare and CR Bard Inc., will bring additional resources and expertise to the AngioSoma team.

AngioSoma, Inc. has added Dr. Leonard Wisneski, MD, FACP as the Chair of the Medical Advisory Board.

AngioSoma, Inc. (OTC PINK:SOAN) has added Darryl Morris as a Strategic Economic Advisor. Morris has over three decades of economic, strategic, and market intelligence experience working with companies, such as Abbott Laboratories.

eQuine Holdings, a Class II Multi-Family Office, has disclosed an eight percent (8%) equity stake in AngioSoma (OTC-PINK:SOAN).

AngioSoma (OTC: SOAN) announced today the launch of their new ecommerce site for its retail brand, SomaCeuticals™.

Law Firm Selected Because of Their Commitment to Excellence and Securities Expertise.

AngioSoma, Inc. is excited to announce that we have identified a regulatory firm who can assist taking our patented flagship drug, Liprostin™, through the FDA approval process.